Skip Navigation


Nucleic Acids Research Advance Access originally published online on February 10, 2009
Nucleic Acids Research 2009 37(6):1925-1935; doi:10.1093/nar/gkp048
This Article
Right arrow Full Text Freely available
Right arrow Print PDF (3652K) Freely available
Right arrow Screen PDF (550K) Freely available
Right arrow Supplementary Data
Right arrowOA All Versions of this Article:
37/6/1925    most recent
gkp048v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Citing Articles
Right arrowScopus Links
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Moreno, P. M. D.
Right arrow Articles by Smith, C. I. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moreno, P. M. D.
Right arrow Articles by Smith, C. I. E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2009, Vol. 37, No. 6 1925-1935
© 2009 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Chemistry and Synthetic Biology

A synthetic snRNA m3G-CAP enhances nuclear delivery of exogenous proteins and nucleic acids

Pedro M. D. Moreno1,*, Malgorzata Wenska2, Karin E. Lundin1, Örjan Wrange3, Roger Strömberg2 and C. I. Edvard Smith1,*

1Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Karolinska University Hospital, SE-141 86 Huddinge, 2Department of Biosciences and Nutrition, Karolinska Institutet, Novum, SE-141 57 Huddinge and 3Department of Cell and Molecular Biology, The Medical Nobel Institutet, Box 285, Karolinska Institutet, Stockholm SE-171 77, Sweden

*To whom correspondence should be addressed. Tel: +0046858583663; Fax: +0046858583650; Email: pedro.moreno{at}ki.se Correspondence may also be addressed to C. I. Edvard Smith. Tel: +0046858583651; Fax: +0046858583650; Email: edvard.smith{at}ki.se

Received January 7, 2009. Revised January 16, 2009. Accepted January 16, 2009.

Accessing the nucleus through the surrounding membrane poses one of the major obstacles for therapeutic molecules large enough to be excluded due to nuclear pore size limits. In some therapeutic applications the large size of some nucleic acids, like plasmid DNA, hampers their access to the nuclear compartment. However, also for small oligonucleotides, achieving higher nuclear concentrations could be of great benefit. We report on the synthesis and possible applications of a natural RNA 5'-end nuclear localization signal composed of a 2,2,7-trimethylguanosine cap (m3G-CAP). The cap is found in the small nuclear RNAs that are constitutive part of the small nuclear ribonucleoprotein complexes involved in nuclear splicing. We demonstrate the use of the m3G signal as an adaptor that can be attached to different oligonucleotides, thereby conferring nuclear targeting capabilities with capacity to transport large-size cargo molecules. The synthetic capping of oligos interfering with splicing may have immediate clinical applications.


The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.